These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31685468)

  • 1. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.
    Bunnell KL; Pai MP; Sikka M; Bleasdale SC; Wenzler E; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V; Zeitlinger M
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ; Zhao M; Andes DR
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.
    Ullah S; Matzneller P; Zeitlinger M; Fuhr U; Taubert M
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1097-1106. PubMed ID: 31062064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.
    Lodise TP; Butterfield JM; Hegde SS; Samara E; Barriere SL
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2062-6. PubMed ID: 22252799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis.
    Rohani R; Hoff B; Jain M; Philbrick A; Salama S; Cullina JF; Rhodes NJ
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):199-209. PubMed ID: 34882292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
    Epps QJ; Epps KL; Young DC; Zobell JT
    Pediatr Pulmonol; 2020 Jan; 55(1):33-57. PubMed ID: 31609097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
    Fusco NM; Toussaint KA; Prescott WA
    Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
    Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.
    Bernstein AT; Leigh MW; Goralski JL; Esther CR; McKinzie CJ
    J Cyst Fibros; 2018 Nov; 17(6):e48-e50. PubMed ID: 30170755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.